Sugi Predict

Sugi Predict / Compounds / SCHEMBL19088636

SCHEMBL19088636

SCHEMBL19088636

COC(=O)CC(C(=O)OCc1ccccc1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ABCB1 P08183 2/20 0.54
▸ REN P00797 1/20 0.47
▸ SYK P43405 1/20 0.43
▸ MMP13 P45452 1/20 0.43
▸ MAOB P27338 1/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ POLB P06746 1/20 0.40
▸ ITGA4 P13612 1/20 0.40
▸ ITGB7 P26010 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HDAC3 O15379 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ NCOR2 Q9Y618 1/20 0.39
▸ KLK7 P49862 1/20 0.39
▸ KLK5 Q9Y337 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20480994 1.00 ABCB1 (0.54) ABCB1RENSYKMMP13MAOB
SCHEMBL18256433 1.00 ABCB1 (0.54) ABCB1RENSYKMMP13MAOB
SCHEMBL16286028 0.89 ABCB1 (0.49) ABCB1RENSYKMAOBL3MBTL1
SCHEMBL19244966 0.88 ABCB1 (0.47) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL18256442 0.88 ALDH1A1 (0.44) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL23279574 0.86 ALDH1A1 (0.42) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL18256462 0.86 ALDH1A1 (0.42) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL23811003 0.85 L3MBTL1 (0.45) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL23879166 0.83 ABCB1 (0.48) ABCB1RENSYKMMP13L3MBTL1
SCHEMBL13707765 0.83 L3MBTL1 (0.42) ABCB1SYKMMP13L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
US-12415796-B2 Inhibitors of (αv)(β6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-09-16 — — US disclosed
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2024-10-03 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
EP-3397638-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2023-08-23 — — EP disclosed
CN-116283977-A Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-06-23 — — CN disclosed
CN-110573499-B Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-04-21 — — CN disclosed
EP-4159727-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2023-04-05 — — EP disclosed
WO-2022109363-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. (US) 2022-05-27 — — WO disclosed
EP-4001279-A1 NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS Enanta Pharmaceuticals, Inc. (US) 2022-05-25 — — EP disclosed
EP-3922639-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2021-12-15 — — EP disclosed
US-20210276975-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2021-09-09 — — US disclosed
US-11046669-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-29 — — US disclosed
US-11040955-B2 Inhibitors of (alpha-v)(beta-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-22 — — US disclosed
EP-3298027-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2021-04-28 — — EP disclosed
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-05-21 — — US disclosed
US-20200087299-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-03-19 — — US disclosed
CN-110573499-A inhibitors of α v β 6 integrin 莫菲克医疗股份有限公司 2019-12-13 — — CN disclosed
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2018-08-30 — — US disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ABCB1 1066/4885REN 1730/4885SYK 881/4885
US-20210276975-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ABCB1 1066/4885REN 1730/4885SYK 881/4885
US-12415796-B2 Inhibitors of (αv)(β6) integrin ITGB6, ITGA6, ITGAV ABCB1 1204/4885REN 1987/4885SYK 925/4885
US-20200087299-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGAV, ITGA6 ABCB1 1311/4885REN 1165/4885SYK 1216/4885
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ABCB1 1044/4885REN 1911/4885SYK 836/4885
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ABCB1 1066/4885REN 1730/4885SYK 881/4885
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV ABCB1 1066/4885REN 1730/4885SYK 881/4885
US-11040955-B2 Inhibitors of (alpha-v)(beta-6) integrin ITGB6, ITGA6, ITGAV ABCB1 1066/4885REN 1730/4885SYK 881/4885
US-11046669-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV ABCB1 1044/4885REN 1911/4885SYK 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.